The Technical Analyst
Vanguard Information Tech [VGT]
Exchange: NYSE
Vanguard Information Tech Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.15% $514.67
America/New_York / 9 mai 2024 @ 10:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 73 170 mill |
| EPS: | 13.48 |
| P/E: | 38.17 |
| Earnings Date: | N/A |
| SharesOutstanding: | 142.17 mill |
| Avg Daily Volume: | 0.448 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.60x |
| Company: PE 38.17 | sector: PE 23.85 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 2.82x |
| Company: PE 38.17 | industry: PE 13.52 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 503.71 - 522.01 ( +/- 1.78%) |
| ATR Model: 14 days |
Forecast:
12:18 - $512.86
Live Trading Signals (every 1 min)
Forecast
1: 10:48 - $514.42
Forecast 2: 11:38 - $513.20
Forecast 3: 12:18 - $512.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $514.67 (-0.15% ) |
| Volume | 0.132 mill |
| Avg. Vol. | 0.448 mill |
| % of Avg. Vol | 29.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VGT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VGT
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the information technology sector, as classified under the Global Industry Classification Standard. The Advisor attempts to replicate the target index by seeking to invest all, or substantially all, of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Latest Press Releases
2024-01-28 15:40:00 - Press Release
Vergent Bioscience Presents Phase 2 Data Showing Vgt-309 Visualizes Tumors In The Lung During Surgery
Minneapolis--(business wire)--vergent bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th annual meeting of the society of thoracic surgeons (#sts2024). the data demonstrate that vgt-309, the company's investigational tumor-targeted fluorescent imaging agent, visualizes primary and metastatic tumor tissue in the lung during surgery. the findings reinforce results from earlier clinical trials of vgt-309 which.
2024-01-17 08:15:00 - Press Release
Vergent Bioscience To Present New Efficacy Results From Phase 2 Clinical Trial Of Vgt-309 At Annual Meeting Of The Society Of Thoracic Surgeons
Minneapolis--(business wire)--vergent bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that new results from the phase 2 clinical program evaluating the company's investigational agent vgt-309 will be presented at sts 2024, the 60th annual meeting of the society of thoracic surgeons, taking place january 27-29, 2024, in san antonio, texas. “our vgt-309 clinical program has produced an encouraging body of evidence demonstrating the potential.
2023-12-13 08:15:00 - Press Release
Vergent Bioscience Initiates Phase 2, Multi-center Visualize Study Evaluating Efficacy Of Tumor-targeted Fluorescent Imaging Agent Vgt-309 In Lung Cancer Surgeries
Minneapolis--(business wire)--vergent bioscience initiates phase 2 visualize study evaluating efficacy of tumor-targeted fluorescent imaging agent vgt-309 in lung cancer surgeries.
2023-08-16 10:10:00 - Press Release
Vergent Bioscience To Present Phase 2 Clinical Data For Vgt-309 At Iaslc 2023 World Conference On Lung Cancer
Minneapolis--(business wire)--vergent bioscience to present phase 2 clinical data for vgt-309 at iaslc 2023 world conference on lung cancer.
Latest News
2024-05-03 11:01:21 - Zacks Investment Research
ETFs to Buy on Apple's Q2 Earnings Beat, Largest-Ever Buyback
Apple beat estimates on both earnings and revenues, and unveiled a record share buyback program amid the steep decline in iPhone sales.
2024-04-29 09:05:00 - The Motley Fool
3 Magnificent Growth ETFs Every Investor Under 40 Should Own
One Nasdaq-tracking fund has a long history of outperformance, and recently came out with a version with even lower fees. This low-cost ETF will give you exposure to the red hot technology sector.
2024-04-24 12:01:09 - Zacks Investment Research
What's in Store for Microsoft ETFs This Earnings Season?
Microsoft (MSFT) has been caught in a spree of heavy technology sector sell-off in recent weeks, erasing most of its gains made this year. There might be gains in store if MSFT comes up with an earnings beat as demand for generative AI will continue to fuel cloud business.
2024-04-23 13:00:31 - Zacks Investment Research
Apple ETFs in Tug-of-War Ahead of Q2 Earnings
Apple (AAPL) has been an underperformer this year. While Bank of America is bullish on Apple's future prospects, Morgan Stanley and UBS are not hopeful on the stock.
2024-04-19 00:39:49 - Seeking Alpha
VGT: This Is The Problem With Buying At Record Valuations
The Vanguard Information Technology ETF has underperformed cash since its 2021 peak, yet its valuation multiple has increased owing to portfolio rebalancing in favor of Nvidia and away from Apple. Extreme valuations, rising Treasury yields and corporate bond yields, and the break of the uptrend warn of another 38% decline as we saw following the 2021 peak. With a dividend yield of just 0.7%, a 10% RRR would mean VGT dividends would have to grow by 9.3% indefinitely.
2024-04-18 08:15:00 - The Motley Fool
3 Vanguard Funds That Can Serve as a Complete Portfolio
Low-cost index funds are an easy way to build wealth. Vanguard, a top fund family, offers an array of high-performance ETFs with ultra-low expense ratios.
2024-04-07 11:10:56 - Seeking Alpha
Better Than Venture Capital: Why I Choose VGT Over Its Top Holdings Or QQQ
The VGT ETF focuses on US Information Technology companies and has a low expense ratio compared to similar technology-focused funds. VGT offers wide exposure to US tech companies and is a preferable option than picking directly its top holdings or choosing the popular Nasdaq 100 QQQ ETF. VGT has historically outperformed the Nasdaq 100, making it more successful than most venture capital funds. Its recent gains have been further boosted by the rise of NVIDIA.
2024-04-05 03:17:59 - Seeking Alpha
ETFs Which Have The Best Chance Of Outperforming For The Rest Of 2024
2024-03-28 07:21:23 - Zacks Investment Research
Should You Invest in the Vanguard Information Technology ETF (VGT)?
Launched on 01/26/2004, the Vanguard Information Technology ETF (VGT) is a passively managed exchange traded fund designed to provide a broad exposure to the Technology - Broad segment of the equity market.
2024-03-20 11:00:28 - Zacks Investment Research
Global ETFs Soar to Record $12.3 Trillion
The global ETF market has been witnessing an unprecedented surge, with the AUM reaching a milestone of $12.3 trillion at the end of February.